The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Angiotensin II for the Treatment of Vasodilatory Shock
Open accessAbstract
BACKGROUND: Vasodilatory shock that does not respond to high-dose vasopressors is associated with high mortality. We investigated the effectiveness of angiotensin II for the treatment of patients with this condition. METHODS: We randomly assigned patients with vasodilatory shock who were receiving more than 0.2 μg of norepinephrine per kilogram of body weight per minute or the equivalent dose of another vasopressor to receive infusions of either angiotensin II or placebo. The primary end point was a response with respect to mean arterial pressure at hour 3 after the start of infusion, with response defined as an increase from baseline of at least 10 mm Hg or an increase to at least 75 mm Hg, without an increase in the dose of background vasopressors. RESULTS: A total of 344 patients were assigned to one of the two regimens; 321 received a study intervention (163 received angiotensin II, and 158 received placebo) and were included in the analysis. The primary end point was reached by more patients in the angiotensin II group (114 of 163 patients, 69.9%) than in the placebo group (37 of 158 patients, 23.4%) (odds ratio, 7.95; 95% confidence interval [CI], 4.76 to 13.3; P<0.001). At 48 hours, the mean improvement in the cardiovascular Sequential Organ Failure Assessment (SOFA) score (scores range from 0 to 4, with higher scores indicating more severe dysfunction) was greater in the angiotensin II group than in the placebo group (-1.75 vs. -1.28, P=0.01). Serious adverse events were reported in 60.7% of the patients in the angiotensin II group and in 67.1% in the placebo group. Death by day 28 occurred in 75 of 163 patients (46%) in the angiotensin II group and in 85 of 158 patients (54%) in the placebo group (hazard ratio, 0.78; 95% CI, 0.57 to 1.07; P=0.12). CONCLUSIONS: Angiotensin II effectively increased blood pressure in patients with vasodilatory shock that did not respond to high doses of conventional vasopressors. (Funded by La Jolla Pharmaceutical Company; ATHOS-3 ClinicalTrials.gov number, NCT02338843 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“There are data from RCTs in specific conditions such as pneumonia (286-289), urinary tract infections (290), bacteremia (291, 292), and intraabdominal infections (293).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [291]
Experimental — accuracy not yet measuredIn the citing paper
“The primary endpoint, an increase of MAP of at least 10 mmHg or to at least 75 mmHg, was achieved in 114 of 163 patients in the angiotensin II group and in 37 of 158 patients in the placebo group (69.9% vs 23.4%, p < 0.001).”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [366]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 15,518
APACHE II-A Severity of Disease Classification System
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,379
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,371
Comparison of Dopamine and Norepinephrine in the Treatment of Shock
De Backer, D., Biston, P., Devriendt, J., Madl, C., Chochrad, D., Aldecoa, C., Brasseur, A., Defrance, P., Gottignies, P., & Vincent, J.-L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907118 · Cited by 1,940
Mayr, F., Yende, S. P., & Angus, D. C. (2013) · Virulence · doi:10.4161/viru.27372 · Cited by 1,298
López, A., Lorente, J. A., Steingrub, J. S., Bakker, J., McLuckie, A., Willatts, S. M., Brockway, M., Anzueto, A., Holzapfel, L., Breen, D. P., et al. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000105581.01815.c6 · Cited by 917
Morelli, A., Ertmer, C., Westphal, M., Rehberg, S. W., Kampmeier, T., Ligges, S., Orecchioni, A., D’Egidio, A., D''Ippoliti, F., Raffone, C., et al. (2013) · JAMA · doi:10.1001/jama.2013.278477 · Cited by 739
History about the discovery of the renin-angiotensin system.
Basso, N., & Terragno, N. (2001) · HYPERTENSION · doi:10.1161/hy1201.101214 · Cited by 236
Survival After Shock Requiring High-Dose Vasopressor Therapy
Brown, S. M., Lanspa, M. J., Jones, J. P., Kuttler, K. G., Li, Y., Carlson, R., Miller, R. R., Hirshberg, E. L., Grissom, C. K., & Morris, A. H. (2013) · CHEST Journal · doi:10.1378/chest.12-1106 · Cited by 211
Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study
Chawla, L. S., Busse, L., Brasha-Mitchell, E., Davison, D., Honiq, J., Alotaibi, Z., & Seneff, M. G. (2014) · Critical Care · doi:10.1186/s13054-014-0534-9 · Cited by 197
Self-citationElbers, P., & İnce, C. (2006) · Critical Care · doi:10.1186/cc4969 · Cited by 155
Angiotensin II in septic shock
Corrêa, T. D., Takala, J. A., & Jakob, S. M. (2015) · Critical Care · doi:10.1186/s13054-015-0802-3 · Cited by 106
Therapeutic Strategies for High-Dose Vasopressor-Dependent Shock
Bassi, E., Park, M., & Azevedo, L. C. P. (2013) · Critical Care Research and Practice · doi:10.1155/2013/654708 · Cited by 106
Angiotensin for septic shock unresponsive to noradrenaline
Yunge, M. (2000) · Archives of Disease in Childhood · doi:10.1136/adc.82.5.388 · Cited by 65
Angiotensin II in Refractory Septic Shock
Antonucci, E., Gleeson, P. J., Annoni, F., Agosta, S., Orlando, S., Taccone, F. S., Velissaris, D., & Scolletta, S. (2016) · Shock · doi:10.1097/shk.0000000000000807 · Cited by 64
Severe septic shock unresponsive to noradrenaline
Wray, G. M., & Coakley, J. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91933-3 · Cited by 63
Clinical Experience with Angiotensin II in the Treatment of Shock
Greco, F. (1961) · JAMA · doi:10.1001/jama.1961.03040490020005 · Cited by 54
THE HEMODYNAMIC EFFECTS OF ANGIOTONIN IN NORMAL MAN 1
Bradley, S. E., & Parker, B. (1941) · Journal of Clinical Investigation · doi:10.1172/jci101265 · Cited by 50
Administration of angiotensin II in refractory septic shock
Thomas, V., & NIELSEN, M. S. (1991) · Critical Care Medicine · doi:10.1097/00003246-199108000-00020 · Cited by 49
Chawla, L. S., Russell, J. A., Bagshaw, S. M., Shaw, A., Goldstein, S. L., Fink, M. P., & Tidmarsh, G. F. (2017) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)00743-3 · Cited by 39
Self-citationAdjunctive Use of a Biologic Pressor Agent, Angiotensin, in Management of Shock
Derrick, J. R., ANDERSON, J. R., & ROLAND, B. J. (1962) · Circulation · doi:10.1161/01.cir.25.1.263 · Cited by 38
Struthers, A. D., Pai, S. M., Seidelin, P. H., Coutie, W. J., & Morton, J. J. (1987) · Journal of Hypertension · doi:10.1097/00004872-198712000-00006 · Cited by 28
Cyclooxygenase inhibition reveals synergistic action of vasoconstrictors on mesangial cell growth
Inoue, T., Mi, Z., Gillespie, D. G., & Jackson, E. K. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00720-1 · Cited by 17
Flagged first, then by citations
Research works printed but not linked: 2
- Chawla LS, 2017, Crit Care Resusc, 19, 43
- Bassi E, 2013, Crit Care Res Pract, 2013, 654708
Cited by
Sorted by citations
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationTrends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask‐Andersen, M., Schiöth, H. B., & Gloriam, D. E. I. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,714
Cecconi, M., Evans, L., Levy, M., & Rhodes, A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30696-2 · Cited by 2,254
Peerapornratana, S., Manrique‐Caballero, C. L., Gómez, H., & Kellum, J. A. (2019) · Kidney International · doi:10.1016/j.kint.2019.05.026 · Cited by 1,557
Metadata
- Authors
- Khanna, A., English, S. W., Wang, X. S., Ham, K., Tumlin, J., Szerlip, H., Busse, L. W., Altaweel, L., Albertson, T. E., Mackey, C., McCurdy, M. T., Boldt, D. W., Chock, S., Young, P. J., Krell, K., Wunderink, R. G., Ostermann, M., Murugan, R., Gong, M. N., Panwar, R., Hästbacka, J., Favory, R., Venkatesh, B., Thompson, B. T., Bellomo, R., Jensen, J., Kroll, S., Chawla, L. S., Tidmarsh, G. F., & Deane, A. M.
- Affiliations
- Cleveland Clinic (US)
- Regions Hospital (US)
- Inova Health System (US)
- Albert Einstein College of Medicine (US)
- University of Maryland, Baltimore (US)
- Northwestern University (US)
- ORCID
- Khanna, Ashish
- English, Shane W.
- Ham, Kealy
- Szerlip, Harold
- Busse, Laurence W.
- Albertson, Timothy E.
- McCurdy, Michael T.
- Young, Paul J.
- Wunderink, Richard G.
- Ostermann, Marlies
- Murugan, Raghavan
- Gong, Michelle N.
- Panwar, Rakshit
- Hästbacka, Johanna
- Venkatesh, Balasubramanian
- Thompson, B. Taylor
- Bellomo, Rinaldo
- Chawla, Lakhmir S.
- Deane, Adam M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-03
- Volume
- 377
- Issue
- 5
- Pages
- 419-430
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2614578436
- Cited by
- 916
- References
- 24
- Citations by year
- 2026: 100 · 2025: 103 · 2024: 121 · 2023: 103 · 2022: 90 · 2021: 95 · 2020: 123 · 2019: 80 · 2018: 75 · 2017: 25
- FWCI
- 64.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Figshare (submittedVersion)
- Työväentutkimus Vuosikirja (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- GlaxoSmithKline
- La Jolla Pharmaceutical Company
- Alexion Pharmaceuticals
- Regeneron Pharmaceuticals
- Genentech
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Hemodynamic Monitoring and Therapy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Trauma, Hemostasis, Coagulopathy, Resuscitation
- Keywords
- angiotensin II, vasodilatory shock, septic shock, vasopressors, norepinephrine, mean arterial pressure, SOFA score, mortality, blood pressure response, adverse events, sepsis treatment, vasopressor-refractory shock, fluid resuscitation, vasopressor dose reduction, organ dysfunction, 28-day mortality
- MeSH terms
- Aged, Angiotensin II, Blood Pressure, Catecholamines, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypotension, Male, Middle Aged, Shock, Vasoconstrictor Agents, Organ Dysfunction Scores
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
